CHMP calls for Novartis drug to be used to cut risk of postoperative DMO
This article was originally published in Scrip
Members of the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) are recommending that Nevanac nepafenac from Alcon Laboratories, now owned by Novartis, should be used to reduce the risk of postoperative macular oedema associated with cataract surgery in diabetic patients. The non-steroidal anti-inflammatory prodrug of amfenac was approved to treat and prevent postoperative pain and inflammation associated with cataract surgery in the US in 2005 and the European Union in 2007.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.